Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ: TEM), a company applying AI solutions to healthcare, has seen its stock perform exceptionally well this year. Investors have found the ...

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics ("Ambry"), which closed on February 3, 2025. Combined with $260 million of capital provided in ...

Tempus AI has a twelve month low of $22.89 and a twelve month high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Insider Activity ...

TEM opened at $49.10 on Thursday. Tempus AI has a 12-month low of $22.89 and a 12-month high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of ...

CHICAGO (AP) — CHICAGO (AP) — Tempus AI Inc. (TEM) on Monday reported a loss of $13 million in its fourth quarter. The Chicago-based company said it had a loss of 8 cents per share.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom ...

Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest since its successful IPO in June 2024. The stock had been on a strong ...

Popular investor Cathie Wood and her Ark Invest funds took advantage of a buying opportunity on Tuesday by purchasing over 400,000 shares of Tempus AI (TEM) as the stock plummeted 15%. This move ...